US FDA declines to approve Scholar Rock's muscle weakness drug

Scholar Rock (SRRK.O) received a Complete Response Letter from the FDA, declining approval for its rare neuromuscular disease drug, apitegromab, due to manufacturing issues at a third-party Catalent facility, now owned by Novo Nordisk (NOVOb.CO). These facility-specific observations, which were not related to Scholar Rock's drug itself, have also caused delays and rejections for Regeneron's (REGN.O) products, indicating a broader compliance challenge at the site. Scholar Rock's shares were halted, and the company plans to resubmit its application once Catalent successfully remediates the FDA's concerns, underscoring the regulatory risks associated with contract manufacturing organizations.

Analysis

Scholar Rock (SRRK) has received a Complete Response Letter (CRL) from the U.S. FDA, declining approval for its rare neuromuscular disease drug, apitegromab. The rejection is not based on the drug's clinical data but is attributed to unresolved manufacturing observations at a third-party fill-finish facility in Indiana. This facility, operated by Catalent and recently acquired by Novo Nordisk, has become a point of systemic regulatory risk, having also caused delays and rejections for Regeneron's (REGN) products. The halting of SRRK shares underscores the material impact of this setback. While the issue is external to Scholar Rock's drug development, the CRL introduces a significant and indefinite delay to the commercialization timeline for apitegromab, as a successful resubmission is now contingent on the remediation efforts and subsequent FDA re-inspection of the Catalent/Novo Nordisk site. This event highlights the critical vulnerability of biotech companies to the operational and compliance integrity of their contract manufacturing organization (CMO) partners.

Key Decisions for Investors

• Investors should re-evaluate valuation models for Scholar Rock (SRRK), as the indefinite delay in apitegromab's approval will postpone its revenue-generating potential, likely leading to a negative re-rating once trading resumes.
• Monitor communications from Catalent and its new owner, Novo Nordisk, regarding the timeline for remediation of the Indiana facility, as this is now the critical path gating item for Scholar Rock's resubmission.
• Assess portfolio exposure to other biotech firms reliant on this specific Catalent facility or other single-source CMOs, as this event demonstrates a systemic risk that can impact multiple companies and lead to correlated negative events.